These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9359070)

  • 21. Malignant hyperthermia phenotype: hypotension induced by succinylcholine in susceptible swine.
    Sigg DC; Iaizzo PA
    Anesthesiology; 2000 Jun; 92(6):1777-88. PubMed ID: 10839930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignant hyperthermia: pharmacology of triggering.
    Hopkins PM
    Br J Anaesth; 2011 Jul; 107(1):48-56. PubMed ID: 21624965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant hyperthermia in plastic surgery.
    Wackym PA; Dubrow TJ; Abdul-Rasool IH; Lesavoy MA
    Plast Reconstr Surg; 1988 Nov; 82(5):878-82. PubMed ID: 3174876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Succinylcholine-induced "masseter spasm".
    Baraka A
    Middle East J Anaesthesiol; 1997 Jun; 14(2):73-6. PubMed ID: 9258882
    [No Abstract]   [Full Text] [Related]  

  • 25. Suxamethonium, masseter spasm and later malignant hyperthermia.
    Ramirez JA; Cheetham ED; Laurence AS; Hopkins PM
    Anaesthesia; 1998 Nov; 53(11):1111-6. PubMed ID: 10023282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volatile anesthetics and succinylcholine in cardiac ryanodine receptor defects.
    Swan H; Laitinen PJ; Toivonen L
    Anesth Analg; 2004 Aug; 99(2):435-7, table of contents. PubMed ID: 15271719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old.
    Lavezzi WA; Capacchione JF; Muldoon SM; Sambuughin N; Bina S; Steele D; Brandom BW
    Anesth Analg; 2013 Feb; 116(2):420-3. PubMed ID: 23267001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Muldoon S; Bünger R
    Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Masseter spasm induced by succinylcholine in children: contracture testing for malignant hyperthermia: report of six cases.
    Flewellen EH; Nelson TE
    Can Anaesth Soc J; 1982 Jan; 29(1):42-9. PubMed ID: 7055743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia.
    Dexter F; Epstein RH; Wachtel RE; Rosenberg H
    Anesth Analg; 2013 Jan; 116(1):118-22. PubMed ID: 23223104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Helsinki Declaration on Patient Safety in Anaesthesiology - Part 3: SOP for malignant hyperthermia].
    Schuster F; Johannsen S; Roewer N
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2013 Mar; 48(3):162-4. PubMed ID: 23592246
    [No Abstract]   [Full Text] [Related]  

  • 32. Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle.
    Glover L; Heffron JJ; Ohlendieck K
    J Appl Physiol (1985); 2004 Jan; 96(1):11-8. PubMed ID: 12959958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant hyperthermia and muscular dystrophies.
    Gurnaney H; Brown A; Litman RS
    Anesth Analg; 2009 Oct; 109(4):1043-8. PubMed ID: 19762730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility?
    Flewellen EH; Nelson TE
    Anesth Analg; 1984 Jul; 63(7):693-7. PubMed ID: 6731899
    [No Abstract]   [Full Text] [Related]  

  • 36. Recognizing and treating malignant hyperthermia.
    Corvetto MA; Taekman JM
    Simul Healthc; 2010 Jun; 5(3):169-72. PubMed ID: 20651479
    [No Abstract]   [Full Text] [Related]  

  • 37. [Cardiac arrest during anesthesia induction with halothane and succinylcholine in an infant. Massive hyperkalemia and rhabdomyolysis in suspected myopathy and/or malignant hyperthermia].
    Mehler J; Bachour H; Simons F; Wolpers K
    Anaesthesist; 1991 Sep; 40(9):497-501. PubMed ID: 1952045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muscle biopsy for malignant hyperthermia screening in children.
    Ummenhofer W; Roesslein R; Sutter PM; Moser N; Kern C; Urwyler A
    Eur J Pediatr Surg; 1997 Oct; 7(5):259-62. PubMed ID: 9402480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant hyperthermia: a case report in Thai Anesthesia Incidents Study (THAI Study).
    Pulnitiporn A; Charuluxananan S; Inphum P; Kitsampanwong W
    J Med Assoc Thai; 2005 Nov; 88 Suppl 7():S149-52. PubMed ID: 16862689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.